2010
A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G-Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway
Sahara M, Sata M, Morita T, Nakajima T, Hirata Y, Nagai R. A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G-Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway. Arteriosclerosis Thrombosis And Vascular Biology 2010, 30: 1315-1324. PMID: 20413734, DOI: 10.1161/atvbaha.109.201327.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis Inducing AgentsAnimalsCapillariesCell HypoxiaCell MovementCells, CulturedCollateral CirculationCyclic GMPCyclic GMP-Dependent Protein KinasesCyclic Nucleotide Phosphodiesterases, Type 5Disease Models, AnimalEndothelial CellsGreen Fluorescent ProteinsHindlimbHumansHypoxia-Inducible Factor 1, alpha SubunitImidazolesIschemiaMaleMiceMice, Inbred C3HMice, Inbred C57BLMice, KnockoutMice, TransgenicMuscle, SkeletalNeovascularization, PhysiologicNitric Oxide Synthase Type IIIPhosphodiesterase 5 InhibitorsPhosphodiesterase InhibitorsPiperazinesRecovery of FunctionRegional Blood FlowRNA InterferenceSignal TransductionStem CellsSulfonesTime FactorsTransfectionTriazinesVardenafil DihydrochlorideVascular Endothelial Growth Factor AConceptsEndothelial progenitor cellsVascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayIschemia-induced angiogenesisGrowth factor pathwaysIschemic muscleMobilization of EPCsSca-1/flkFactor pathwaySoluble guanylate cyclase inhibitorEndothelial nitric oxide synthasePhosphodiesterase-5 inhibitor vardenafilRight femoral arteryBlood flow recoveryEffect of vardenafilPhosphodiesterase-5 inhibitionUnilateral hindlimb ischemiaGuanylate cyclase inhibitorVascular endothelial growth factorNitric oxide synthaseUpregulated protein expressionProtein kinase G inhibitorIschemic cardiovascular diseaseCapillary-like tube formationEndothelial growth factor
2006
New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension
Sahara M, Takahashi T, Imai Y, Nakajima T, Yao A, Morita T, Hirata Y, Nagai R. New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension. Cardiovascular Drugs And Therapy 2006, 20: 377-386. PMID: 17124557, DOI: 10.1007/s10557-006-0498-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnticoagulantsAntihypertensive AgentsCalcium Channel BlockersDiureticsDrug Therapy, CombinationHumansHypertension, PulmonaryMaleMiddle AgedNicorandilNitric Oxide DonorsOxygen Inhalation TherapyPhosphodiesterase InhibitorsPiperazinesPurinesPyridazinesSildenafil CitrateSulfonesVasodilator AgentsConceptsPulmonary arterial hypertensionFunctional class IVArterial hypertensionNew York Heart Association functional class IVNYHA functional class IVPhosphodiesterase type 5 inhibitorsClass IVIntravenous prostacyclin therapyOral combination therapyRational pharmacological therapyFirst-line therapyPhosphodiesterase type 3 inhibitorPrimary pulmonary hypertensionEndothelin receptor antagonistsCurrent treatment optionsCalcium channel blockersLong-term efficacyType 5 inhibitorsNovel therapeutic approachesLong-term survivalProstacyclin therapyExercise tolerancePulmonary hypertensionMale patientsPharmacological therapy